

 Shared health Soins communs Manitoba	M37.2 - TICAGRELOR (<i>BRILINTA</i>)	
	MEDICATION STANDING ORDER	
Version date: 2023-07-23		Effective date: 2023-09-19 (0700 hrs)

INDICATIONS
<ul style="list-style-type: none"> Known or suspected ST elevation myocardial infarction (STEMI) if patient is going directly to primary coronary intervention (PCI) and <u>only after consultation with the Code-STEMI physician</u>

CONTRAINDICATIONS
<ul style="list-style-type: none"> Patient may be candidate for fibrinolysis with TNK Active bleeding that cannot be controlled by basic measures or at a non-compressible site True allergy to ticagrelor

ROUTE (WORK SCOPE)	INITIAL DOSE	REPEAT DOSE
ORAL (PCP & ABOVE)	17 years & older - 180 mg (2 tablets)	None

NOTES
1. None

APPROVED BY	
	
Medical Director - Provincial EMS/PT	Associate Medical Director - Provincial EMS/PT

VERSION CHANGES (refer to X08 for change tracking)

- Revised administration table presents information for scope / route / dose more clearly